Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 281

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the D-HART Pilot Study)

Open access
Van Tassell, Benjamin Wallace, Arena, Ross, Biondi-Zoccai, Giuseppe, McNair Canada, Justin, Oddi, Claudia, Abouzaki, Nayef Antar, Jahangiri, Arehzo, Falcao, Raquel Appa, Kontos, Michael Christopher, Shah, Keyur Bharat, Voelkel, Norbert Felix, Dinarello, Charles Anthony, Abbate, Antonio·2014·The American Journal of Cardiology

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of exercise intolerance due to impaired myocardial relaxation and/or increased stiffness. Patient with HFpEF often show signs of chronic systemic inflammation and experimental studies show that interleukin-1 (IL-1), a key pro-inflammatory cytokine, impairs myocardial relaxation. The aim of the current study was to determine the effects of IL-1 blockade with anakinra on aerobic exercise capacity in patients with HFpEF and plasma C-reactive protein (CRP) >2 mg/l (reflecting increased IL-1 activity). Twelve patients were enrolled in a double-blind, randomized, placebo-controlled, cross-over trial and assigned 1:1 to receive one of the 2 treatments (anakinra 100 mg or placebo) for 14 days and then an additional 14 days of the alternate treatment (placebo or anakinra). Cardiopulmonary exercise testing (CPX) was performed at baseline, after the first 14 days and after the second 14 days. Placebo-corrected interval change in peak oxygen consumption (VO2) was chosen as primary endpoint. All 12 patients enrolled in the study and receiving treatment completed both phases, and experienced no major adverse events. Anakinra led to a statistically significant improvement in peak VO2 (+1.2 ml•kg−1•min−1, P=0.009), and a significant reduction in plasma CRP levels (−74%, P=0.006). The reduction in CRP levels was correlated with the improvement in peak VO2 (R=-0.60, P=0.002). Three patients (25%) had mild and self-limiting injection site reactions. In conclusion, IL-1 blockade with anakinra for 14 days significantly quenches the systemic inflammatory response and improves aerobic exercise capacity in patients with HFpEF and elevated plasma CRP levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2013.08.047

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 281

Metadata

Authors
Van Tassell, B. W., Arena, R., Biondi-Zoccai, G., McNair Canada, J., Oddi, C., Abouzaki, N. A., Jahangiri, A., Falcao, R. A., Kontos, M. C., Shah, K. B., Voelkel, N. F., Dinarello, C. A., & Abbate, A.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2014-01
Volume
113
Issue
2
Pages
321-327
ISSN
0002-9149 (ISSN-L)
OpenAlex
W2171449411
Cited by
281
References
1
FWCI
38.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the D-HART Pilot Study). https://app.cochat.ai/papers/10.1016/j.amjcard.2013.08.047
The paper
Van Tassell, B. W., Arena, R., Biondi-Zoccai, G., McNair Canada, J., Oddi, C., Abouzaki, N. A., Jahangiri, A., Falcao, R. A., Kontos, M. C., Shah, K. B., Voelkel, N. F., Dinarello, C. A., & Abbate, A. (2014). Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the D-HART Pilot Study). The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2013.08.047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.